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Objectives We tested the hypothesis that serum total testosterone and sex hormone–binding globulin (SHBG) levels predict
cardiovascular (CV) events in community-dwelling elderly men.
Background Low serum testosterone is associated with increased adiposity, an adverse metabolic risk profile, and athero-
sclerosis. However, few prospective studies have demonstrated a protective link between endogenous testoster-
one and CV events. Polymorphisms in the SHBG gene are associated with risk of type 2 diabetes, but few stud-
ies have addressed SHBG as a predictor of CV events.
Methods We used gas chromatography/mass spectrometry to analyze baseline levels of testosterone in the prospective
population-based MrOS (Osteoporotic Fractures in Men) Sweden study (2,416 men, age 69 to 81 years). SHBG
was measured by immunoradiometric assay. CV clinical outcomes were obtained from central Swedish registers.
Results During a median 5-year follow-up, 485 CV events occurred. Both total testosterone and SHBG levels were in-
versely associated with the risk of CV events (trend over quartiles: p  0.009 and p  0.012, respectively). Men
in the highest quartile of testosterone (550 ng/dl) had a lower risk of CV events compared with men in the
3 lower quartiles (hazard ratio: 0.70, 95% confidence interval: 0.56 to 0.88). This association remained after
adjustment for traditional CV risk factors and was not materially changed in analyses excluding men with known
CV disease at baseline (hazard ratio: 0.71, 95% confidence interval: 0.53 to 0.95). In models that included both
testosterone and SHBG, testosterone but not SHBG predicted CV risk.
Conclusions High serum testosterone predicted a reduced 5-year risk of CV events in elderly men. (J Am Coll Cardiol 2011;
58:1674–81) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.019H
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(Testosterone has important metabolic actions in men,
affecting body composition and exerting direct effects on
insulin sensitivity and lipid metabolism (1). In accordance,
low serum testosterone is associated with increased adipos-
ity, an adverse metabolic risk profile, and atherosclerosis
(1,2). Recently, much interest has focused on testosterone
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support the beneficial metabolic effects of testosterone
supplementation in men with low testosterone levels (4).
owever, a recent clinical trial reported that transdermal
estosterone therapy increased the risk of cardiovascular
CV) events (5).
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October 11, 2011:1674–81 Testosterone and Cardiovascular Events in MenAlthough most cross-sectional studies have found lower
testosterone levels in patients with coronary heart disease
(CHD) (6), population-based prospective studies report
conflicting results regarding the association between total
testosterone and CV mortality (7–13). Few of these studies
addressed a possible link between testosterone levels and
CV events other than mortality; the Health in Men Study
(14) found that both low total testosterone and free testos-
terone were associated with an increased risk of incident
stroke, but other studies (13,15,16) reported no association
between testosterone levels and CV events. Given the
conflicting results of the relatively few studies addressing
the association between endogenous testosterone and
CV events in men, there is a need for large epidemiologic
studies with complete follow-up of CV endpoints, in which
serum testosterone levels are assayed by state-of-the-art
methodology.
Sex hormone-binding globulin (SHBG) is an important
determinant of total testosterone levels (3,17). Insulin re-
sistance and obesity are associated with low SHBG (1), and
it is generally accepted that insulin inhibits the hepatic
production of SHBG (1). Interestingly, a recent study
showed that polymorphisms in the SHBG gene, affecting
serum levels of SHBG, are prospectively associated with the
risk of type 2 diabetes, suggesting a causal role for low
SHBG in cardiometabolic risk (18). However, studies that
addressed SHBG as a predictor of CV events report
inconsistent results, and most lack data on concurrent
testosterone levels (11,12,14,19,20).
We therefore tested the hypothesis that serum testoster-
one, assessed by gas chromatography/mass spectrometry,
and/or SHBG levels predict CV events in a prospective
study of community-dwelling elderly men.
Methods
Study population. The multicenter MrOS (Osteoporotic
Fractures in Men) study includes older men in Sweden,
Hong Kong, and the United States. In Sweden, study
participants (men age 69 to 81 years) were randomly
selected from national population registers (21). Eligibility
for study participation required the ability to walk unassisted
by another person, no bilateral hip prosthesis, the ability to
provide self-reported data, and the ability to understand and
sign an informed consent; 45% of those contacted partici-
pated in the MrOS study in Sweden (n  3,014), which
includes cohorts in 3 cities: Malmö (n  1,005), Göteborg
(n  1,010), and Uppsala (n  999). The study was
approved by the ethics committees at Göteborg University,
Lund University, and Uppsala University.
We investigated the associations between total and free
serum testosterone and SHBG with CV events in the
Swedish MrOS cohort. Serum samples were drawn in the
morning (before 10 AM; 69% of the cohort) or aroundoon (between 10 AM and 3 PM, average 1 PM; 31%). eerum for assessment of testos-
erone by gas chromatography/
ass spectrometry was available
or 2,639 men (99% of the par-
icipants in the Göteborg co-
ort, 96% in the Malmö cohort,
nd 68% in the Uppsala co-
ort). Of these, 223 participants
ere excluded for the following
easons: treatment with testos-
erone, 5-reductase inhibitors,
gonadotropin-releasing hormone
agonists, or antiandrogens or a
history of surgical castration.
This left 2,416 men in the pres-
ent study sample.
Assessment of covariates. We used a standardized ques-
tionnaire (22) to gather information about smoking
habits and physical activity as well as self-reported
medical diagnoses (hypertension, diabetes, stroke, myo-
cardial infarction, or angina pectoris). We defined previ-
ous CHD as a history of myocardial infarction and/or
angina pectoris and CV disease as a history of stroke or
CHD. Hypertension was defined as hypertension diag-
nosis with either self-reported antihypertensive treatment
or a measured systolic blood pressure of 140 mm Hg
(supine blood pressure, measured after a 10-min rest).
Standard equipment was used to measure height and
weight; body mass index (BMI) was calculated as kg/m2
(weight [kg]/height [m]2). Apolipoprotein (Apo) B and
poA1 were determined by immunoprecipitation en-
anced by polyethylene glycol at 340 nm (Thermo Fisher
cientific, Vantaa, Finland); analyses were performed on
Konelab 20 autoanalyzer (Thermo Fisher Scientific),
nd the interassay coefficient of variation was 5%.
erum sex steroids and SHBG. All samples were frozen at
80oC and shipped on dry ice to 1 laboratory. A validated
as chromatography/mass spectrometry system (23–25) was
sed to measure testosterone (detection limit  0.05 ng/ml;
ntra-assay coefficient of variation, 2.9%; interassay coeffi-
ient of variation, 3.4%) and estradiol (detection limit 
.00 pg/ml; intra-assay coefficient of variation, 1.5%, inter-
ssay coefficient of variation, 2.7%) in baseline serum
amples. The analytes and the internal standard were
etected using an HP5973 quadruple mass spectrometer
quipped with a chemical ionization source (Agilent Tech-
ologies, Santa Clara, California). To measure serum
HBG, we used an immunoradiometric assay (Orion Di-
gnostics, Espoo, Finland; limit of detection, 1.3 nmol/l;
ntra-assay coefficient of variation, 3%; interassay coefficient
f variation, 7%; reference ranges for apparently healthy
dult men provided by the manufacturer were 16 to 61
mol/l). We calculated free testosterone according to the
ethod described by Vermeulen et al. (26) and van den Beld
Abbreviations
and Acronyms
Apo  apolipoprotein
BMI  body mass index
CHD  coronary heart
disease
CI  confidence interval
CV  cardiovascular
HR  hazard ratio
ICD  International
Classification of Diseases
SHBG  sex hormone-
binding globulint al. (27), taking concentrations of total testosterone and
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tration (43 g/l).
Study outcomes. Follow-up time was recorded as the
period between the baseline visit (in the period 2001 to
2004) and date of death, CV event, or last data collection
(December 31, 2008). Cause of death data were collected
from the Swedish Cause of Death Register, held by the
National Board of Health and Welfare in Sweden, in which
all deaths in Sweden are registered with International
Classification of Diseases (ICD) codes based on the infor-
mation from death certificates. Data were collected from
this register from study start until December 31, 2005, and
from evaluation of copies of death certificates for deaths
occurring after this date up to 2008. Based on the informa-
tion from the register/death certificate, the underlying cause
of death was determined for each participant and classified
as CHD (ICD-10 codes I20 to I25), stroke (ICD-10 codes
I60 to I64), or other. Data on hospitalization for first acute
myocardial infarction (ICD-10 codes I21 to I23), unstable
angina (ICD-10 codes I20.0 and I24), revascularization
procedure (surgery code FN), stroke (ICD-10 codes I60 to
I64), or transient ischemic attack (ICD-10 code G45) were
collected from the Swedish Hospital Discharge Register
between the baseline date and December 31, 2008. The
combination of data from the Swedish Cause of Death
Registry and the Swedish Hospital Discharge Register is an
efficient, validated alternative to hospital discharge notes
and death certificates for both CHD and stroke (28). Major
CV events were defined as a composite endpoint of CHD
events (hospitalization for acute myocardial infarction, un-
stable angina or revascularization, or death from CHD) and
cerebrovascular events (hospitalization for stroke or tran-
sient ischemic attack, or death from stroke).
Statistical analysis. We used Cox proportional hazards
regression to analyze the associations between serum testos-
terone, SHBG, and CV outcomes. In predefined analyses,
total and free testosterone, SHBG, and estradiol were
Baseline Characteristics of the Whole Sample and by Quartile GrouTable 1 Baseline Characteristics of the Whole Sample and by Q
Variable
Whole Sample
(n  2,416)
Testos
1
(n  604)
2
(n  610)
Age, yrs 75.4 3.2 75.5 3.2 75.5 3.1
BMI, kg/m2 26.4 3.6 28.1 3.9 26.7 3.4
ApoB/A1 ratio 0.72 0.20 0.75 0.20 0.74 0.2
Physical activity, km/day 3.9 3.1 3.4 2.7 3.9 3.1
Current smoking, % 8.4 7.8 7.4
Diabetes, % 9.4 15.8 10.8
Hypertension, % 33.7 41.2 37.5
History of CV disease, % 26.2 31.7 31.0
Testosterone, ng/dl 454 173 255 74 389 28
SHBG, nmol/l 44 22 32 18 39 15
Free testosterone, pg/ml 81 31 54 20 74 16
Estradiol, pg/ml 21 7 17 7 20 6Values aremean SD or %. *p value indicates significance for trend across quartiles of testosterone. †p va
ApoA1  apolipoprotein A1; ApoB  apolipoprotein B; BMI  body mass index; CV  cardiovascular;examined as quartiles based on distribution in the entire
study population. Based on the observed distribution, tes-
tosterone was further examined as a dichotomous variable
comparing quartile 4 with quartiles 1 to 3. All estimates
were adjusted for age, morning sample (yes/no), and for
MrOS study site. Further adjustments were made for BMI
(log transformed), ApoB/A1 ratio, physical activity (kilo-
meters walked per day, entered as quartiles because of a
non-normal distribution), and 3 dichotomous variables:
current smoking, diabetes, and hypertension. Hazard ratios
(HRs) were computed for the total cohort and the cohort
without baseline history of CV disease. To test whether the
associations varied by age, we tested the interaction terms
age · testosterone (entered as a dichotomous variable, quartile 4 or
quartiles 1 to 3) in the Cox regression model. Unadjusted
Kaplan-Meier survival curves illustrated the association
between testosterone levels and CV events as well as CHD
events and cerebrovascular events, and the log-rank test
assessed statistical significance. The baseline frequencies of
smoking, diabetes, hypertension, and history of CV disease
across testosterone quartiles were tested by the chi-square
test (trend across quartiles and quartile 4 vs. quartiles 1 to 3).
For continuous baseline variables (age, BMI, ApoB/A1
ratio, physical activity, and hormone levels), the correspond-
ing analyses were performed by linear regression and t test.
We performed statistical analyses using SPSS for Windows
version 18.0 (SPSS Inc., Chicago, Illinois).
Results
The baseline characteristics of the whole cohort as well as
trends across quartiles of serum total testosterone levels are
shown in Table 1. With increasing levels of testosterone,
BMI, ApoB/A1 ratio, and the prevalence of diabetes and
hypertension decreased, whereas physical activity increased.
Smoking was more common among those with the highest
testosterone levels. Prevalent CV disease was inversely
Serum Testosteroneile Group of Serum Testosterone
Quartile
p Value*
Trend Across Quartiles
p Value†
Q4 vs. Q1–3
3
(n  596)
4
(n  606)
75.4 3.1 75.3 3.3 0.18 0.18
25.8 3.1 24.9 3.0 0.001 0.001
0.72 0.19 0.68 0.21 0.001 0.001
4.1 3.3 4.2 3.3 0.001 0.003
7.6 10.9 0.058 0.010
5.9 5.3 0.001 0.001
33.0 25.3 0.001 0.001
25.4 17.1 0.001 0.001
491 31 680 127 — —
45 18 59 27 0.001 0.001
89 22 109 34 0.001 0.001
22 6 26 8 0.001 0.001p ofuart
terone
0lue indicates significance between subjects in quartiles 1 to 3 and quartile 4 of serum testosterone.
Q  quartile; SHBG  sex hormone–binding globulin.
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October 11, 2011:1674–81 Testosterone and Cardiovascular Events in Menassociated with testosterone levels at baseline; a history of
CV disease was almost twice as common among participants
in testosterone quartiles 1 and 2 compared with those in the
highest quartile of testosterone.
The median follow-up time for major CV events was 5.1
years (11,605 person-years). Except for 3 participants who
moved abroad, there was no loss to follow-up in the study.
During the 5-year follow-up, 485 participants experienced a
major CV event (rate of 4.2 per 100 person-years at risk).
Pre-specified analyses based on quartiles of hormone
levels revealed an inverse association between quartiles of
both total testosterone and SHBG and any major CV event
(Table 2), whereas the association between free testosterone
and CV risk was not statistically significant (p  0.061).
sing men in quartile 1 of total testosterone levels as a
eference, the risk of experiencing a major CV event
ecreased in men in quartile 4, whereas the risk in the
ndividual quartiles 2 and 3 was similar to that of quartile 1.
e therefore pooled quartiles 1 to 3 of total testosterone in
ubsequent analyses. As shown in Table 2, men in the
ourth quartile of testosterone were at a lower risk of CV
HRs for Major CV Events AcrossQuartiles of Serum T s oste ne,SHBG, Free T stosterone, and Estradiol
Table 2
HRs for Major CV Events Across
Quartiles of Serum Testosterone,
SHBG, Free Testosterone, and Estradiol
No. of Major
CV Events/
No. at Risk HR (95% CI) p Value
Testosterone, ng/dl
Q1 (340) 128/604 1.00 (referent)
Q2 (341–438) 134/610 1.02 (0.80–1.30) 0.88
Q3 (439–549) 128/596 0.96 (0.75–1.23) 0.74
Q4 (550) 95/606 0.71 (0.54-0.93) 0.013
Per-quartile increase 0.90 (0.83–0.97) 0.009
Q4 vs. Q1–3 0.70 (0.56–0.88) 0.002
Q4 vs. Q1–3, adjusted for SHBG* 0.75 (0.59–0.96) 0.024
SHBG, nmol/l
Q1 (29.2) 144/599 1.00 (referent)
Q2 (29.3–39.4) 125/599 0.86 (0.68–1.10) 0.22
Q3 (39.5–53.2) 103/600 0.71 (0.55–0.93) 0.011
Q4 (53.2) 110/599 0.77 (0.60–1.00) 0.050†
Per-quartile increase 0.90 (0.83–0.98) 0.012
Per-quartile increase, adjusted for
testosterone‡
0.94 (0.86–1.03) 0.17
Free testosterone, pg/ml
Q1 (62.2) 129/599 1.00 (referent)
Q2 (62.4–78.9) 123/599 0.95 (0.74–1.22) 0.68
Q3 (78.9–98.0) 118/600 0.84 (0.65–1.09) 0.18
Q4 (98.2) 112/599 0.84 (0.64–1.10) 0.20
Per-quartile increase 0.92 (0.85–1.00) 0.061
Estradiol, pg/ml
Q1 (16.1) 123/605 1.00 (referent)
Q2 (16.1–20.2) 116/601 0.89 (0.69–1.15) 0.37
Q3 (20.3–25.1) 129/606 0.98 (0.77–1.27) 0.90
Q4 (25.1) 117/604 0.90 (0.70–1.17) 0.43
Per-quartile increase 0.98 (0.91–1.07) 0.70
Values are adjusted for age, Osteoporotic Fractures in Men study site, and morning sample. *SHBG0
entered as quartiles. †p  0.05. ‡Testosterone entered as Q4 versus Q1 to Q3.
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.vents compared with men in the pooled quartiles 1 to 3
p  0.002). The risk of major CV events across SHBG
uartiles displayed a different pattern; men in both individ-
al quartiles 3 and 4 were at lower risk of a major CV event
ompared with men in quartile 1. In similar analyses, there
as no association between estradiol levels and CV risk
Table 2).
Because of the biological interplay between testosterone
nd SHBG and because both low total testosterone and
HBG levels were associated with CV risk, we next studied
he impact of adjusting the testosterone-CV event associa-
ion for SHBG and vice versa. The association between
igh testosterone levels and reduced risk of any major CV
vent remained after adjusting for the SHBG quartile
Table 2); a similar result was obtained if SHBG was
ntered as below/above the median level (HR: 0.75, 95%
I: 0.59 to 0.96; p  0.021). In contrast, the association
etween SHBG and CV risk was no longer statistically
ignificant after adjustment for testosterone levels entered
ither as quartile 4 versus quartiles 1 to 3 (Table 2) or as
ndividual quartiles (HR: 0.94, 95% CI: 0.85 to 1.03;
 0.17).
To study the potential modifying effect of age with the
ssociation between higher testosterone levels and reduced
V risk, we tested the interaction term age · testosterone in
he Cox regression model; the result (p 0.51) indicated no
ignificant interaction with age (data not shown).
We also calculated the HRs for CV disease outcomes by
he highest quartile of testosterone in the whole cohort and
he cohort without baseline CV disease. As shown in
igures 1A and 1B, the HR for a major CV event limited to
he 1,777 men without baseline CV disease was 0.71 (95%
I: 0.53 to 0.95; p  0.021), similar to the HR for the total
ohort (0.70, 95% CI: 0.56 to 0.88; p  0.002), despite the
maller number of major CV events (n  260 in the 1,777
en at risk).
In exploratory post hoc analyses, we examined whether
estosterone was associated with the risk of a CHD or a
erebrovascular event. The numbers of CHD events per
estosterone quartile were 80 in quartile 1, 80 in quartile 2,
2 in quartile 3, and 60 in quartile 4. The corresponding
umbers for cerebrovascular events were 56, 66, 57, and 46,
espectively. In analyses for CHD outcomes, high testoster-
ne levels were inversely associated with CHD risk in the
otal cohort (quartile 4 vs. quartiles 1 to 3 of testosterone,
R: 0.72, 95% CI: 0.54 to 0.96, p 0.025) (Fig. 1C). After
xcluding participants with previous CHD (532 participants
ith 137 events), the point estimate for CHD risk was
imilar (HR: 0.75, 95% CI: 0.52 to 1.09), but the associa-
ion was no longer statistically different (Fig. 1D). There
as a nonsignificant trend for the association of high
estosterone levels with cerebrovascular events in the whole
ohort (HR: 0.76, 95% CI: 0.55 to 1.05, p  0.091)
Fig. 1E), which was similar after exclusion of 155 partici-
ants with 34 previous stroke events (HR: 0.72, 95% CI:
.50 to 1.02, p  0.063) (Fig. 1F).
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Testosterone and Cardiovascular Events in Men October 11, 2011:1674–81Kaplan-Meier curves of CV event-free survival stratified
by total testosterone level also illustrate that men in the
highest quartile of testosterone had lower risk of a major CV
event (Fig. 2A) (log-rank test, p 0.002). In corresponding
Kaplan-Meier models for CHD and cerebrovascular events,
CHD events (log-rank test, p  0.026), but not cerebro-
vascular events (p  0.092), were significantly associated
with high testosterone levels (Figs. 2B and 2C).
Because testosterone was associated with CV risk even
after adjustment for SHBG levels, and not vice versa, we
performed sensitivity analyses for the association between
testosterone levels and CV risk, including analyses that
excluded participants with a follow-up time of 2.6 years or
less (one-half of the median follow-up time), to reduce the
potential effect of subclinical or unrecognized disease. CV
risk results were unchanged after this exclusion (Table 3).
Figure 1 HRs for CV Events by Quartile of Total Testosterone
Forest plots showing hazard ratios (HRs) and 95% confidence intervals (CIs) by qu
coronary heart disease (CHD) events (C, D), and cerebrovascular (CBV) events (E,
Data are adjusted for age, Osteoporotic Fractures in Men study site, and morningFurther, the association between high testosterone and lowCV risk was attenuated, but remained statistically signifi-
cant after adjustment for the traditional CV risk factors
shown in Table 3.
Discussion
In this prospective population-based study of elderly Swed-
ish men followed for 5 years, both serum total testosterone
and SHBG levels were inversely associated with the risk of
CV events. In analyses that included both testosterone and
SHBG, high testosterone but not SHBG predicted reduced
fatal and nonfatal CV events. Men in the highest quartile of
testosterone had lower risk of CV events compared with
men in the 3 lower quartiles, and this association remained
after adjustment for traditional CV risk factors and after
Q) of total testosterone levels for major cardiovascular (CV) events (A, B),
the whole cohort (A, C, E) and in subjects without previous disease (B, D, F).
e. *Data from Table 2.artile (
F), in
samplexcluding men with prevalent CV disease.
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October 11, 2011:1674–81 Testosterone and Cardiovascular Events in MenIn a recent small controlled trial of older men selected for
impaired physical activity, relatively large doses of exoge-
nous testosterone were associated with an increased risk of
adverse CV events (5). This raised concerns about the
benefit and safety of testosterone as a cardioprotective agent
in older men. In contrast, a recent systematic review and
meta-analysis of testosterone trials found no similar harm
(29). The data presented here suggest that high endogenous
testosterone levels (the highest quartile) are associated with
reduced, rather than increased, CV risk in elderly men.
Previous cohort studies of the association between serum
testosterone levels and CV events found contradictory
results. Large population-based prospective studies reported
both an inverse association (Rancho Bernardo [7], Euro-
pean Investigation into Cancer-Norfolk [8], Study of
ealth in Pomerania [9], Caerphilly [10]) or no association
Massachusetts Male Aging Study [11], National Health
nd Nutrition Examination Survey [12], Tromsö [13])
etween total testosterone and CV disease mortality. Re-
ently, low testosterone levels were shown to predict an
ncreased risk of combined fatal and nonfatal stroke in
ommunity-dwelling men with a median age of 76 years
14). There was a nonsignificant trend toward an inverse
ssociation between serum testosterone and incident CHD
vents in the Caerphilly study (10), and other large
opulation-based studies addressing testosterone as a pre-
ictor of CV events (Rancho Bernardo [15], Framingham
16], Tromsö [13]) show no association. Thus, our findings
f a significant inverse association between testosterone
evels and risk of combined fatal and nonfatal CV events
n men support and extend previous work showing
n association between testosterone and CV mortality
7–10,14). Our study differs from previous studies that all
sed immunoassay-based hormone assay methods; ours is
he first study addressing the association between CV
vents and serum testosterone assessed by a mass spec-
rometry– based technique, which provides more accurate
ssessment of testosterone than immunoassay-based
echniques (30).
In the present study, testosterone levels in the highest
uartile were associated with reduced CV risk compared
ith lower levels (quartiles 1 to 3). It is biologically plausible
hat serum testosterone less than a certain serum level
onfers increased cardiometabolic risk. Adverse effects of
estosterone deficiency on, for example, body composition,
nsulin sensitivity, and systemic inflammation, may mediate
uch an effect (1,6). This notion is further supported by the
act that androgen-deprivation therapy in prostate cancer
atients increases CV risk (31). In line with previous studies
6), we found that men with high serum testosterone levels
ad lower BMI and ApoB/A1 ratio, were more physically
ctive, and had a lower frequency of reported diabetes,
ypertension, and prevalent CV disease. Although testos-
erone is associated with an adverse metabolic risk profile,
he association between testosterone and risk of CV eventsFigure 2 Kaplan-Meier Plots by Testosterone Levels
Kaplan-Meier curves of event-free survival by serum testosterone for major CV
events (A) CHD events (B), and CBV events (C). In quartile 4 of serum testos-
terone (green lines) or quartiles 1 to 3 (blue lines). p value assessed by log-
rank test. Abbreviations as in Figure 1.emained statistically significant, albeit slightly attenuated,
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This may suggest that other mechanisms, such as endothe-
lial regeneration, could be important (32).
Although there are several possible mechanisms by which
testosterone potentially reduces CV risk, it is important to
note that any severe illness can suppress testosterone pro-
duction (3,33). Thus, any acute or chronic illness may
concomitantly reduce testosterone production and increase
the risk of a CV event. Because the elderly are more likely
than younger adults to have CV or other diseases, a high
testosterone level in elderly men may be a sign of good
general health and thereby associated with reduced risk of
CV events. However, the absence of statistical evidence of
an interaction with age does not support this thesis, but the
age range was fairly narrow. Further, exclusion of the first
2.6 years of follow-up did not attenuate the association,
arguing against an important role for baseline (sub)acute
systemic disease. In addition, excluding men with prevalent
CV disease did not materially change the HRs for CV risk.
Nevertheless, studies addressing testosterone levels, assessed
by mass spectrometry–based techniques, as predictors of
CV events in relatively younger and presumably healthier
men are of continued interest.
In the present study, low SHBG levels predicted an
increased risk of CV events. Ours is the first study demon-
strating an association between SHBG and the risk of
combined fatal and nonfatal CV events. Two previous
studies found an association between low SHBG levels and
mortality from CV disease and/or CHD (11,19), whereas
other studies found no similar association (12,14,20). Yeap
et al. (14) found no association between SHBG and
incident stroke/transient ischemic attack. In the present
study, the association between SHBG and CV risk was no
longer significant after adjustment for testosterone levels,
suggesting that the covariation of SHBG with testosterone
levels may explain some or all of its association with
cardiometabolic risk (18).
In the present study, free testosterone levels were weakly
and not significantly associated with CV risk, despite a
trend toward an inverse association. Most previous studies
of testosterone and CV endpoints did not study free or
bioavailable testosterone (8–10,16). Some studies (7,14)
found similar associations for free (or bioavailable) and total
HRs of Testosterone (Q4 vs. Pooled Q1 to Q3) fFirst Year f Follow-Up Excluded and AdjustmeTable 3 HRs f Testosterone (Q4 vs. PooledFirst Years of Follow-Up Excluded a
Whole sample, adjusted for age*
Excluding first 2.6 yrs† of follow-up, adjusted for age*
Whole sample, adjusted for CV risk factors‡
Values in italics are from Table 2. *Adjusted for age, Osteoporotic F
follow-up time 5.1 years. ‡Adjusted for age, Osteoporotic Fractures in M
ApoB/A1 ratio, and physical activity.
Abbreviations as in Tables 1 and 2.testosterone, whereas others (11,12) found discordant re- dsults. The Massachusetts Male Aging Study (11) reported a
direct association between free testosterone and mortality
from ischemic heart disease. Thus, data regarding free
testosterone and CV events are inconsistent. There are
iffering opinions regarding the merits of calculated free
estosterone values because these estimates show larger
ariability (34). However, they are mainly influenced (80%
f attributable variance) by the variability of the total
estosterone assay and less influenced (14%) by the equa-
ions used (35). Thus, if sensitive and accurate measure-
ents of testosterone are used, calculated free testosterone
hould provide an accurate estimate of free testosterone
36). The Vermeulen formula used in the present study has
een shown to be in good agreement with equilibrium
ialysis measurements (26,27).
tudy limitations. The results are based on single mea-
urements of sex steroids and SHBG and may underesti-
ate the true associations. Given the diurnal variation in
erum testosterone levels (37), the use of some nonmorning
amples may contribute to increased variability and under-
stimation of serum testosterone levels in the present study.
owever, the diurnal variation of serum testosterone is less
n older men (70 years; 10% lower levels at 4 PM than at 8
AM) (37), and the hour of day was adjusted for in these
nalyses. Another limitation is that baseline diabetes, hy-
ertension, and CV disease were at least in part self-
eported. More important, older adults are often treated
ith medications that might alter CV risk and/or testoster-
ne levels, which were not examined in this report. In
ddition, our results are limited to elderly Swedish men.
urther, our post-hoc analyses using a dichotomous variable
omparing quartile 4 with quartiles 1 to 3 were not adjusted
or multiple comparisons. The study also has considerable
trengths, including the mass spectrometry–based method-
logy, the large well-characterized sample, complete follow-
p, fatal and nonfatal outcomes, and the documented
ccuracy of classification in nationwide Swedish registers
28).
onclusions
igher serum testosterone levels are associated with a
educed risk of fatal and nonfatal CV events in community-
ajor CV Events,r Covariatesto Q3) for Major CV Events,
djustment for Covariates
No. of Events/
No. at Risk
Testosterone
Q4 vs. Q1–Q3
HR (95% CI) p Value
485/2,416 0.70 (0.56–0.88) 0.002
252/2,126 0.71 (0.52–0.96) 0.029
454/2,267 0.77 (0.60–0.98) 0.032
s in Men study site, and morning sample. †One-half of the median
y site, morning sample, BMI, current smoking, hypertension, diabetes,or Mnt foQ1
nd A
racture
en studwelling elderly men.
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